ETBX 011

Next Previous
Drug Profile

ETBX 011

Alternative Names: Ad5 [E1-, E2B-]-CEA; AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; Adenoviral CEA vaccine; CEA-targeted vaccine - Etubics; ETBX-011

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Etubics Corporation
  • Developer Etubics Corporation; NantCell; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 Jan 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (SC)
  • 08 Jan 2018 NantKwest plans the phase Ib/II QUILT-3.067 trial for Triple negative breast cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (NCT03387085)
  • 29 Dec 2017 NantKwest initiates enrolment in the phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top